Holen Sie sich die Stockscreener-App
1.3486
0.78%
0.0086
Schlusskurs vom Vortag:
$1.34
Offen:
$1.35
24-Stunden-Volumen:
4.51M
Relative Volume:
0.52
Marktkapitalisierung:
$455.82M
Einnahmen:
$4.41M
Nettoeinkommen (Verlust:
$-67.85M
KGV:
-5.9725
EPS:
-0.2258
Netto-Cashflow:
$-57.15M
1W Leistung:
+3.88%
1M Leistung:
-18.65%
6M Leistung:
+14.44%
1J Leistung:
+45.08%
1-Tages-Spanne:
$1.34
$1.41
1-Wochen-Bereich:
$1.30
$1.41
52-Wochen-Spanne:
$0.80
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.3465 | 453.62M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
437.20 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.92 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.45 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.78 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.25 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc stock (US67577C1053): FDA feedback keeps retinitis pigmentosa trial on track - AD HOC NEWS
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Stock Quote & Chart - Ocugen, Inc.
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen closes $130 million convertible notes offering - Investing.com UK
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease - Traders Union
Ocugen Raises $130 Million Through Convertible Notes Offering - TipRanks
Ocugen Announces Interim Chief Medical Officer Appointment Transition - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout
Ocugen closes $130 million convertible notes offering By Investing.com - Investing.com Australia
Ocugen Reports Positive GA Trial Data, Extends Cash Runway - MyChesCo
Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader - Stock Titan
Ocugen (NASDAQ: OCGN) closes $130M 6.75% convertible notes due 2034 - Stock Titan
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences - Sahm
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer - AD HOC NEWS
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
Ocugen brings blindness gene therapy to two May events in 2026 - Stock Titan
Ocugen (OCGN) Reports Q1 EPS - Insider Monkey
Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline - AD HOC NEWS
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop - AD HOC NEWS
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026 - Traders Union
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop By Investing.com - Investing.com South Africa
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop - Investing.com
Ocugen, Inc.Common Stock (NQ: OCGN - FinancialContent
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Pipeline Proof Remains the Prize - AD HOC NEWS
Ocugen stock dips as Q1 losses widen - MSN
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed? - Yahoo Finance
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (OCGN) Upgraded to Buy: Here's Why - Yahoo Finance
Ocugen’s Convertible Lifeline Fuels a Three-Pronged Gene Therapy Sprint - AD HOC NEWS
Ocugen (NASDAQ: OCGN) posts larger Q1 2026 loss and raises $115M in convertible notes - Stock Titan
Number of shareholders of Ocugen Inc – LSX:A2PSZH - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):